US FDA Oncology AdComm's Pediatric Study Reviews Go Virtual

 
• By Sue Sutter

ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.

Young woman's feet dipping slowly in the water.
US FDA's drugs center is dipping its toes in the virtual AdComm waters. • Source: Shutterstock

The COVID-19 outbreak has led the US FDA’s Center for Drug Evaluation and Research to dip its toes into the virtual advisory committee waters with a two-day panel review of pediatric development plans for four oncologic agents.

On 17-18 June, the Oncologic Drugs Advisory Committee’s pediatric oncology subcommittee will convene online to discuss issues related to the...

More from US FDA Performance Tracker

More from Regulatory Trackers